Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration [2] Group 1 - The drug registration certificate signifies regulatory approval for Baricitinib tablets, which may enhance the company's product portfolio and market presence [2] - This approval could potentially lead to increased revenue streams for the company through the commercialization of Baricitinib [2]

泰恩康11月28日公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到国家药品监督管理局 核准签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus 激酶（JAK）抑制剂，可阻断一种或 多种JAK 激酶家族成员的活性，从而抑制激活炎症的途径，由礼来制药公司和Incyte 合作开发。巴瑞替 尼最早于2017年在欧盟和英国上市，获批适应症为类风湿关节炎；2018年获得美国FDA批准被用于治疗 某些患有中度至重度活动性类风湿关节炎的成年患者，2022 年6 月，美国FDA批准了巴瑞替尼口服片剂 用于治疗患有严重斑秃的成年患者。该产品未来的具体销售情况可能受到行业政策、市场环境等因素影 响，具有不确定性。 ...

格隆汇11月28日丨泰恩康(301263.SZ)公布，全资子公司山东华铂凯盛生物科技有限公司于近日收到国 家药品监督管理局（简称"国家药监局"）签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus 激酶(JAK)抑制剂，可阻断一种或多种JAK激酶家族成员的活性，从而抑制激活炎症的途径，由礼来制 药公司和Incyte合作开发。 ...

Core Viewpoint - The company TianKang (301263.SZ) has received a drug registration certificate for Baricitinib tablets from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the pharmaceutical sector [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has been granted the drug registration certificate for Baricitinib tablets [1] - Baricitinib is identified as a Janus kinase (JAK) inhibitor, which can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1]

每经AI快讯，11月28日，泰恩康（301263）公告，公司全资子公司山东华铂凯盛生物科技有限公司收 到国家药品监督管理局签发的巴瑞替尼片《药品注册证书》。该产品用于治疗类风湿关节炎、严重斑秃 等。 ...

智通财经APP讯，泰恩康(301263.SZ)公告，公司全资子公司山东华铂凯盛生物科技有限公司于近日收到 国家药品监督管理局签发的巴瑞替尼片《药品注册证书》。巴瑞替尼是一种Janus激酶(JAK)抑制剂，可 阻断一种或多种JAK激酶家族成员的活性，从而抑制激活炎症的途径。 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-078 广东泰恩康医药股份有限公司 关于全资子公司收到巴瑞替尼片药品注册证书 的公告 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司于近日收到国家药品监督管理局（以下简称"国家药监 局"）签发的巴瑞替尼片《药品注册证书》。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2302467 药品名称：巴瑞替尼片 剂型：片剂 规格：2mg 注册分类：化学药品 4 类 上市许可持有人：山东华铂凯盛生物科技有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规 范要求方可生产销售。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 药品批准文号：国药准字 H20256060 四、对公司的影响及风险提示 该产品未来的具体销售情况可能受到行业政策、市场环境等因素影响，具 有不确定性，敬请广大投资者审慎决 ...

Core Viewpoint - The company TianKang has been recognized for its outstanding practices in ESG (Environmental, Social, and Governance) and rapid growth, winning the "ESG New Star Golden Bull Award Top 20" at the 2025 Golden Bull Enterprise Sustainable Development Forum [1] Group 1: ESG Practices - TianKang focuses on the pharmaceutical health sector, driving development through "innovation + responsibility" [2] - The company optimizes production processes and implements green manufacturing principles, ensuring environmental standards from raw material procurement to waste disposal, aiding the pharmaceutical industry's low-carbon transition [2] - In the social value dimension, TianKang emphasizes research and development in three core areas: sexual health, ophthalmology, and gastrointestinal medications, addressing clinical needs through high-intensity R&D investment [2] Group 2: R&D and Innovation - The company has established a comprehensive independent R&D system, forming a strong product development team with a "pyramid" R&D strategy, focusing on generic drug development as the base, followed by improved chemical drugs and biological drugs, with innovative drug research at the peak [2] - R&D investment as a percentage of revenue increased from 6.90% in 2022 to 21.96% in 2024, with 20 drug registration applications accepted, indicating a robust R&D pipeline [2] - The innovative drug CKBA is expected to fill a gap in domestic vitiligo treatment, targeting a market worth over 10 billion [2] Group 3: Corporate Governance and Future Strategy - TianKang has built a modern corporate governance structure, with management committed to long-termism and no plans for share reduction post-lockup, demonstrating confidence in development [3] - The company is creating a global pharmaceutical innovation sharing platform, combining internal growth with external collaborations to accelerate first-in-class innovative drug development, with projects like CKBA ointment progressing well [3] - TianKang aims to deepen the integration of ESG into its corporate development strategy, enhancing its commitment to social responsibility and product quality while increasing its focus on innovative drug development [3]

Core Viewpoint - The stock of Taiankang has shown significant volatility, with a year-to-date increase of 100.53%, but recent trends indicate a decline over the past 20 and 60 days, raising concerns about its future performance [1][2]. Financial Performance - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, representing a year-on-year decrease of 8.13% [2]. - The net profit attributable to the parent company for the same period was 31.41 million yuan, reflecting a substantial year-on-year decline of 73% [2]. Stock Market Activity - As of November 26, Taiankang's stock price was 29.66 yuan per share, with a market capitalization of 12.62 billion yuan [1]. - The trading volume on that day was 66.90 million yuan, with a turnover rate of 0.75% [1]. - The stock has experienced a net outflow of 4.76 million yuan in principal funds, indicating a lack of strong buying interest [1]. Shareholder Information - As of September 30, the number of shareholders for Taiankang increased to 12,000, a rise of 9.32% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.53% to 25,381 shares [2]. Dividend Distribution - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

Core Viewpoint - The company, Tai En Kang, is poised to address a significant unmet clinical need in the treatment of pediatric vitiligo, with its innovative drug CKBA potentially becoming the first approved treatment for children aged 2-12 years [1] Group 1: Market Opportunity - There are currently no approved drugs for vitiligo in children aged 2-12 globally, and existing therapies are often used off-label [1] - The estimated number of vitiligo patients in China exceeds 30 million, with children accounting for approximately 32%-40% of this population, indicating a substantial market demand [1] - The annual treatment cost for pediatric vitiligo is estimated to be between 15,000 to 20,000 yuan, suggesting a market size exceeding 100 billion yuan [1] Group 2: Product Development - CKBA, derived from natural products like frankincense, is a new immunomodulator that offers greater targeting and safety compared to traditional immunosuppressants, making it particularly suitable for pediatric use [1] - The company anticipates that CKBA cream could be approved as the first innovative drug for treating vitiligo in children aged 2-12, and it is expected to become the preferred option for maintenance therapy [1] - Projections indicate that, once approved, the annual peak sales for CKBA in the pediatric vitiligo market could exceed 5 billion yuan [1] Group 3: Regulatory Progress - On November 20, the company announced that its subsidiary, Bo Chuang Yuan, has had the application for CKBA cream (Class 1 chemical drug) for pediatric vitiligo Phase II clinical trials accepted by the National Medical Products Administration [1]